NEW YORK (GenomeWeb) – CombiMatrix today announced that the New York State Department of Health has approved the firm's CombiSNP Array for Prenatal Diagnosis.

The CombiSNP Array uses chromosomal microarray analysis of chorionic villi and amniocentesis samples to detect chromosomal imbalances not detected by karyotyping.

"The prenatal diagnostic test we offer is important both as a first-tier test and as a tool physicians utilize to confirm the increasing number of positive non-invasive prenatal screening results," CombiMatrix CEO Mark McDonough said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.